Regenxbio Faces Lawsuit Over RGX-111's Alleged Misleading Safety and Efficacy Claims

### RGX-111 Under Fire: Allegations of Misleading Safety and Efficacy Claims

Regenxbio Inc. faces significant legal challenges related to its lead product candidate, RGX-111. A class action lawsuit, filed by DJS Law Group LLP, claims that the company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making false and misleading statements regarding RGX-111’s safety and efficacy. Investors who purchased the company’s shares during the period from February 9, 2022, to January 27, 2026, are encouraged to come forward as the firm seeks potential lead plaintiffs for the case. Notably, the lawsuit highlights the adverse safety events that occurred during clinical trials, particularly the emergence of a tumor in a participant, which the plaintiffs argue Regenxbio did not adequately disclose.

The FDA's decision to place a clinical hold on RGX-111 is central to the allegations. According to the complaint, Regenxbio positioned RGX-111 as a groundbreaking treatment while allegedly concealing critical safety data that would have significantly impacted the investment community's perception and the product's market potential. The firm contends that Regenxbio's communications during this period misled investors and artificially inflated share prices until the unfavorable data was revealed, leading to significant market losses.

Legal representatives of the case, including both DJS Law Group and The Schall Law Firm, are emphasizing the importance of collective action among affected investors. They assert that engaging in these lawsuits can facilitate recovery of damages for those who suffered losses as a result of the alleged misconduct. The firms highlight that participation in the class action does not require formal appointment as a lead plaintiff, thereby encouraging broader involvement from anyone affected by the purported misstatements.

### Other Relevant Developments

The potential implications of this lawsuit extend beyond financial recovery; they pose risks to Regenxbio's reputation and its developmental pipeline. As the company navigates this challenging legal landscape, key stakeholders will closely observe how it manages communications regarding RGX-111 and other candidates moving forward.

With the class action already drawing attention, the legal proceedings may further scrutinize the company’s research and development practices, potentially altering the landscape of investor confidence in Regenxbio and similar biopharmaceutical entities operating within the competitive gene therapy space.